2invest AG
FBSBF
Other OTC15.50
USD
- -
- -
2invest AG
FBSBF
(Other OTC)
Recent
price
15.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- 2invest AG is a Germany-based investment company primarily engaged in acquiring, holding, managing, and selling investments in corporations and partnerships. The company's core business activities focus on investments in the biotechnology, life science, and information technology sectors, both domestically and internationally. It also invests in natural resources and financial instruments, including marketable securities and unlisted companies, with a strategic emphasis on attractive risk-reward profiles to achieve long-term, risk-adjusted total returns. Founded as 4Basebio AG and renamed to 2invest AG in January 2021, the company is headquartered in Germany. 2invest AG's main products and services comprise investment management across various sectors, primarily biotechnology, life sciences, IT, and natural resources. The company engages in the acquisition and disposition of equity and financial stakes in listed and private enterprises worldwide, focusing on innovative companies with strong potential in early-stage cancer drugs and other biotechnology applications. Its portfolio also includes strategic investments in companies such as Neophore Ltd, reflecting a targeted approach to preclinical and development-stage biotech firms. Additionally, 2invest AG provides capital and financial support to these sectors through equity commitments and actively manages its portfolio for financial performance optimization. In the past 1-2 years, 2invest AG has undergone significant changes and strategic developments. In 2021, it executed a major name change from 4Basebio AG to 2invest AG, signaling a broader investment focus beyond biotechnology. It made noteworthy strategic investments, including a GBP 4.5 million commitment to Neophore Ltd, a UK-based biotechnology company specializing in early-stage cancer drugs. Recent shareholder activities include a public share repurchase offer and share exchange process carried out in mid-2024, streamlining its shareholder structure. The company continues to invest aggressively in financial assets and marketable securities, alongside expanding its international footprint and diversifying its portfolio to incorporate natural resource exposures driven by macroeconomic trends. 2invest AG operates primarily in Germany but maintains a global investment scope with involvement in Europe, the UK, and international markets encompassing both listed securities and private equity. The company targets institutional investors and stakeholders seeking exposure to high-growth sectors like biotechnology and IT, leveraging market trends such as increased inflationary pressures and industrial growth. Its investment decision framework integrates financial metrics with qualitative assessments, aiming for long-term value creation and portfolio risk management. Overall, 2invest AG stands as a specialized investment firm founded with a focus on biotechnology and life sciences but has expanded its remit to include broader sectors and geographies. The company is headquartered in Germany, with a market capitalization around €65-75 million as of late 2025, demonstrating ongoing portfolio management and strategic capital deployment in line with evolving market conditions and sector opportunities. It remains a dynamic player in the investment landscape, with recent corporate transitions and sustained focus on sectors with significant growth potential.